SIRPant Immunotherapeutics, Inc.
Monday, February 26, 2024
SIRPant Immunotherapeutics, Inc., a clinical stage company, programs the cells that drive immunity – macrophages – to mobilize effective polyclonal anti-cancer immune responses, providing a novel multipronged approach to combat aggressive tumors.
CEO/Top Company Official
Robert J. Towarnicki
Lead Product in Development
SIRPant-M™ (Autologous Sirpα depleted Macrophage Therapy)
Development Phase of Primary Product
Number Of Unlicensed Products